请选择 进入手机版 | 继续访问电脑版
トップページ News テキスト

Recently, BeiGene announced that the US Food and Drug Administration (FDA) has approved the use of BeiGene (Trastuzumab) in combination with platinum and fluorouracil chemotherapy for first-line treatment of adult patients with unresectable or metastatic HER2 negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (≥ 1).
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

六月清晨搅 注册会员
  • ファン人

    0

  • に注目

    0

  • 文章

    30